ABUS
NASDAQ HealthcareArbutus Biopharma Corporation - Common Stock
Biotechnology
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
๐ Market Data
| Price | $5.01 |
|---|---|
| Volume | 6,457,764 |
| Market Cap | 992.51M |
| Beta | 0.620 |
| RSI (14-Day) | 50.0 |
| 200-Day MA | $4.52 |
| 50-Day MA | $4.78 |
| 52-Week High | $5.45 |
| 52-Week Low | $3.50 |
| P/E Ratio | 6.34 |
| Forward P/E | -30.31 |
| Price / Book | 3.83 |
๐ฏ Investment Strategy Scores
ABUS scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (69/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ช Falling Knife (26/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find ABUS in your text
Paste any article, transcript, or post โ the tool will extract ABUS and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-09-18.